MIT Technology Review
Sep 11, 2020 - 15 min
Why aducanumab provides false hope. The approval of the first Alzheimer’s drug in almost 20 years has left many affected by the disease with hope for the future. But, the drug is surrounded by controversy. Han Yu — the author of "Mind Thief: The Story of Alzheimer’s" — argues that the US Food and Drug Administration's decision masks the fact that we’re still very far from sure what causes the most common form of dementia.